AZN vs BSX
AZN: AstraZeneca is a global pharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to address major unmet medical needs worldwide. BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties.
Side-by-side fundamentals
| Metric | AZN | BSX | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $158.75 | $51.19 | |
| Market cap as of 2026-08-12 | $184.5B | $74.2B | |
| P/E as of 2026-08-12 | 23.84 | 20.00 | BSX lower |
| PEG as of 2026-08-12 | 2.64 | 0.44 | BSX lower |
| Net margin as of 2026-08-12 | +17.0% | +17.5% | BSX higher |
| Gross margin as of 2026-08-12 | +81.3% | +69.8% | AZN higher |
| Operating margin as of 2026-08-12 | +22.8% | +19.8% | AZN higher |
| ROE as of 2026-08-12 | +21.7% | +14.9% | AZN higher |
| ROA as of 2026-08-12 | +9.1% | +8.3% | AZN higher |
| Debt / equity as of 2026-08-12 | 0.64 | 0.43 | BSX lower |
| Revenue growth (YoY) as of 2026-08-12 | +8.6% | +13.5% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +16.5% | BSX higher |
| Dividend yield as of 2026-08-12 | +2.0% | n/a | |
| Beta as of 2026-08-12 | 1.36 | 0.58 | |
| 1-year return as of 2026-08-11 close | +7.2% | -50.2% | AZN higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.